## **Core Concept**
The question tests the understanding of chemotherapeutic agents' mechanisms, specifically those effective in hypoxic tumor conditions. Hypoxic tumor cells are those found in solid tumors with limited blood supply, making them more resistant to conventional chemotherapy and radiation. The correct answer involves a drug that selectively targets these hypoxic cells.

## **Why the Correct Answer is Right**
The correct answer, **.**, refers to a class of drugs known as nitroimidazoles or more specifically, **Mitomycin C** and **Tirapazamine** are examples, but among the given options, the focus is on drugs activated under hypoxic conditions. These drugs are reduced in hypoxic cells to form toxic metabolites that damage DNA, thereby exerting their cytotoxic effects. This mechanism is particularly useful in targeting the hypoxic fraction of tumors, which is often the case in solid tumors.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option does not correspond to a drug known for selective action on hypoxic tumor cells. Without the specific drug name, it's hard to detail, but generally, most conventional chemotherapeutic agents do not have selective action on hypoxic cells.
- **Option B:** Similarly, this option does not represent a drug with selective toxicity towards hypoxic tumor cells. Common chemotherapeutic agents usually work through mechanisms that are not specific to hypoxic conditions.
- **Option D:** This option also does not represent a drug with a known selective action on hypoxic tumor cells. Drugs listed here might work through different mechanisms not specific to hypoxia.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **Tirapazamine** is a bioreductive agent that is activated under hypoxic conditions, making it selectively toxic to hypoxic cells. This is a strategy to overcome the resistance of hypoxic tumor cells to conventional chemotherapy and radiation.

## **Correct Answer:** .